Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

[1]  J. Holst,et al.  Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. , 2005, Diabetes.

[2]  B. Göke,et al.  Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans , 2005, Gut.

[3]  M. Nauck,et al.  Glucagon-like peptide 1 and its derivatives in the treatment of diabetes , 2005, Regulatory Peptides.

[4]  S. Theander,et al.  β-Cell Secretory Products Activate α-Cell ATP-Dependent Potassium Channels to Inhibit Glucagon Release , 2005 .

[5]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[6]  P. Tso,et al.  GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[7]  M. Nauck,et al.  Glucagon‐like peptide 1(GLP‐1) in biology and pathology , 2005, Diabetes/metabolism research and reviews.

[8]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[9]  M. Hanefeld,et al.  The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[10]  D. Drucker.  Enhancing incretin action for the treatment of type 2 diabetes. , 2003, Diabetes care.

[11]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[12]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[13]  M. Taskinen.  Diabetic dyslipidaemia: from basic research to clinical practice* , 2003, Diabetologia.

[14]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[15]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[16]  A. Hamsten,et al.  Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. , 2001, Journal of the American College of Cardiology.

[17]  M. Toborek,et al.  High-Energy Diets, Fatty Acids and Endothelial Cell Function: Implications for Atherosclerosis , 2001, Journal of the American College of Nutrition.

[18]  B. Göke,et al.  Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans , 2000, Gut.

[19]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[20]  J. Holst,et al.  Inhibition of Human Gastric Lipase Secretion by Glucagon-like Peptide-1 , 1998, Digestive Diseases and Sciences.

[21]  R. Krauss,et al.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.

[22]  B. Braden,et al.  The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. , 1995, Gastroenterology.

[23]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[24]  P. Rutgeerts,et al.  Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. , 1993, Gastroenterology.

[25]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[26]  J. K. Dunn,et al.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[28]  G. Boden,et al.  Effects of Lipid on Basal Carbohydrate Metabolism in Normal Men , 1991, Diabetes.

[29]  S. Bonner-Weir,et al.  Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes. , 1990, The Journal of clinical investigation.

[30]  V. Marks,et al.  The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas. , 1988, The Journal of clinical investigation.

[31]  R. Mahler,et al.  THE EFFECT OF INSULIN ON LIPOLYSIS. , 1964, Diabetes.

[32]  S. Theander,et al.  Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. , 2005, Diabetes.

[33]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.